Oculis Holding (OCS) AI Stock Analysis

• Market Cap: $1.26B
• Dividend Yield: N/A
• Average Volume (3M): 58.01K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.28
• Revenue Growth: N/A
• EPS Growth: -25.15%
• Country: US
• Employees: 49
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.40
• Shares Outstanding: 57,169,476
• 10 Day Avg. Volume: 127,612
• 30 Day Avg. Volume: 58,014
• PEG Ratio: 0.25
• Price to Book (P/B): 8.50
• Price to Sales (P/S): 908.96
• P/FCF Ratio: -13.06
• Enterprise Value/Market Cap: 0.55
• Enterprise Value/Revenue: 1.37K
• Enterprise Value/Gross Profit: -48.05
• Enterprise Value/Ebitda: -6.72
• 1Y Price Target: $40.00
• Price Target Upside: 81.57% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $21.50 ▼(-2.41% Downside)

Oculis Holding's overall stock score is primarily impacted by its weak financial performance, with significant operational losses and negative cash flows. While technical indicators show bullish momentum, the valuation remains unattractive due to negative earnings. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Strong Equity Position

An increase in total assets and a strong equity position enhance financial stability and stakeholder confidence, supporting long-term growth.

Low Debt-to-Equity Ratio

Low leverage provides financial flexibility, allowing the company to invest in growth opportunities without significant debt burden.

Amended Loan Agreement

The amended loan agreement enhances financial flexibility and operational capabilities, supporting strategic initiatives and potential expansion.

Negative Factors

Declining Equity

Declining equity can undermine financial health, limiting the company's ability to withstand economic downturns and invest in growth.

Negative Cash Flow

Negative cash flow growth indicates operational inefficiencies, potentially restricting the company's ability to fund R&D and other strategic initiatives.

Operational Losses

Substantial operational losses highlight challenges in achieving profitability, which may hinder long-term sustainability and investor confidence.

Oculis Holding Business Overview & Revenue Model

Company Description

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

How the Company Makes Money

Oculis generates revenue through the development and commercialization of its ophthalmic products. The primary revenue streams include sales of its proprietary drug formulations, licensing agreements with pharmaceutical companies, and collaborations with research institutions and healthcare providers. Oculis may also engage in partnerships that involve joint development of new therapies, which can result in milestone payments and royalties based on sales performance. Additionally, the company may receive funding through grants or investments aimed at supporting its research and development initiatives.

Oculis Holding Financial Statement Overview

Summary

Oculis Holding faces substantial financial challenges, particularly in profitability and revenue growth, with negative margins across the board. While the company maintains a low debt-to-equity ratio, its equity has been declining. Cash flows are under pressure, with negative free cash flow and limited conversion of losses into operational cash flow. Strategic adjustments are necessary to improve financial health.

Income Statement

Oculis Holding's TTM (Trailing-Twelve-Months) income statement shows a gross profit margin of -5747.54% and a net profit margin of -18363.60%, indicating significant operational losses. The revenue growth rate is negative, showing a decrease of 47.11% from the previous year, and both EBIT and EBITDA margins are negative, further emphasizing ongoing financial struggles.

Balance Sheet

The balance sheet reveals a debt-to-equity ratio of 0.02, indicating low leverage, but stockholders' equity has decreased significantly over recent years. The equity ratio is 60.96%, showing a strong equity position relative to total assets, yet the company has faced equity erosion over time.

Cash Flow

Cash flow analysis shows a negative free cash flow growth rate of -11.43%. The operating cash flow to net income ratio is 0.55, reflecting operational inefficiencies. The free cash flow to net income ratio is 0.56, suggesting limited cash flow generation relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	504.00K	686.00K	0.00	0.00	0.00	0.00
Gross Profit	-14.40M	-51.40M	0.00	0.00	0.00	0.00
EBITDA	-102.95M	-72.80M	-87.09M	-31.90M	-13.17M	-12.10M
Net Income	-104.10M	-85.78M	-88.80M	-38.70M	-18.55M	-14.87M
Balance Sheet
Total Assets	167.84M	120.35M	114.35M	37.06M	58.04M	16.38M
Cash, Cash Equivalents and Short-Term Investments	46.44M	98.66M	91.65M	19.79M	46.28M	4.95M
Total Debt	2.47M	1.18M	605.00K	123.08M	114.27M	54.81M
Total Liabilities	37.24M	46.97M	20.63M	135.05M	119.00M	60.04M
Stockholders Equity	130.59M	73.38M	93.73M	-97.99M	-60.95M	-43.65M
Cash Flow
Free Cash Flow	-61.39M	-47.73M	-53.89M	-28.62M	-13.85M	-12.05M
Operating Cash Flow	-59.98M	-47.50M	-53.84M	-25.07M	-13.82M	-12.03M
Investing Cash Flow	-29.43M	-17.56M	-54.21M	-3.55M	-28.00K	-19.00K
Financing Cash Flow	105.43M	54.03M	129.67M	1.71M	55.19M	4.86M

Oculis Holding Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 22.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OCS, the sentiment is Positive. The current price of 22.03 is above the 20-day moving average (MA) of 20.41, above the 50-day MA of 19.91, and above the 200-day MA of 18.77, indicating a bullish trend. The MACD of 0.28 indicates Negative momentum. The RSI at 65.58 is Neutral, neither overbought nor oversold. The STOCH value of 66.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OCS.

Oculis Holding Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRAX	60 Neutral	$8.07B	-22.81	-75.20%	―	364.98%	-25.33%
EYPT	58 Neutral	$1.41B	-5.71	-98.23%	―	-7.38%	-49.03%
SYRE	57 Neutral	$2.34B	-13.84	-32.63%	―	―	-123.65%
SPRY	57 Neutral	$1.08B	-13.51	-45.92%	―	5459.66%	-59.70%
OCS	53 Neutral	$1.26B	-8.75	-80.98%	―	―	-25.15%
UPB	52 Neutral	$1.49B	-12.06	-40.80%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Oculis Holding Corporate Events

Oculis Holding AG Reports Q3 2025 Financial Results

On November 10, 2025, Oculis Holding AG announced its unaudited financial results for the three and nine months ending September 30, 2025. The report highlights an increase in total assets and equity compared to the previous year, indicating a positive financial trajectory. However, the company continues to report losses, reflecting ongoing investments in research and development. This financial update is crucial for stakeholders as it underscores the company’s commitment to growth and innovation in the ophthalmology sector, despite current financial challenges.

The most recent analyst rating on (OCS) stock is a Hold with a $21.50 price target. To see the full list of analyst forecasts on Oculis Holding stock, see the OCS Stock Forecast page.

Oculis Holding AG Secures $110 Million in Oversubscribed Share Offering

On October 29, 2025, Oculis Holding AG announced the pricing of its offerings of 5,432,098 ordinary shares, expected to raise approximately $110 million, with potential to increase to $124.2 million if underwriters exercise their option to purchase additional shares. The proceeds will be used to accelerate the development of Privosegtor for optic neuropathies and support general corporate purposes. The offerings are set to close around November 3, 2025, and are expected to fund operations through late 2028, potentially strengthening Oculis’ market position in the neuro-ophthalmology field.

The most recent analyst rating on (OCS) stock is a Hold with a $21.50 price target. To see the full list of analyst forecasts on Oculis Holding stock, see the OCS Stock Forecast page.

Oculis Holding AG Suspends $100 Million Share Sale Agreement

On October 29, 2025, Oculis Holding AG announced the suspension and termination of its sales agreement prospectus supplement with Leerink Partners LLC, initially set up for the sale of up to $100 million of its ordinary shares. Despite the termination of the ATM Prospectus, no shares had been sold under this agreement, and the sales agreement itself remains in effect, pending the filing of a new prospectus or registration statement.

The most recent analyst rating on (OCS) stock is a Hold with a $21.50 price target. To see the full list of analyst forecasts on Oculis Holding stock, see the OCS Stock Forecast page.

Oculis Advances Privosegtor into Registrational Trials for Neuro-Ophthalmology

On October 6, 2025, Oculis Holding AG announced the advancement of its drug candidate Privosegtor into a registrational program for neuro-ophthalmology indications, following a positive meeting with the FDA. This initiative, known as the PIONEER program, will include three pivotal trials aimed at supporting the registration of Privosegtor for AON and NAION. The trials are expected to generate operational synergies and cost efficiencies, accelerating development timelines. Oculis also reported preliminary financials with approximately $182 million in cash and short-term investments as of September 30, 2025, ensuring a cash runway into the second half of 2027 to support the Privosegtor development program.

The most recent analyst rating on (OCS) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Oculis Holding stock, see the OCS Stock Forecast page.